Oxacillinase-181 Carbapenemase-Producing <i>Klebsiella pneumoniae</i> in Neonatal Intensive Care Unit, Ghana, 2017–2019
Appiah-Korang Labi, Karen Leth Nielsen, Rasmus L. Marvig, Stephanie Bjerrum, Christabel Enweronu‐Laryea, Marc Bennedbæk, Mercy J. Newman, Prosper K Ayibor, Leif Percival Andersen, Jørgen A. L. Kurtzhals
Abstract
C arbapenems are antimicrobial drugs of last re- sort for infections caused by multidrug-resistant gram-negative bacteria. Therefore, the global spread of carbapenemase-producing Enterobacteriaceae, which are resistant to carbapenems, is troubling (1,2). Because of the high number of deaths associated with infections caused by these bacteria, the World Health Organization classifies Enterobacteriaceae as priority organisms for which new antimicrobial drugs are urgently needed (3).
Topics & Concepts
Klebsiella pneumoniaeNeonatal intensive care unitMicrobiologyInfection controlBiologyIntensive care unitKlebsiella infectionsMultiple drug resistanceEnterobacteriaceae InfectionsVirologyMedicineEnterobacteriaceaeAntibioticsIntensive care medicinePediatricsGeneGeneticsEscherichia coliAntibiotic Resistance in BacteriaVibrio bacteria research studiesBacterial biofilms and quorum sensing